Glucosylceramide synthase-IN-3

• UNSPSC Description:

  Glucosylceramide synthase-IN-3 (compound BZ1) is a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 16 nM for human GCS.Glucosylceramide synthase-IN-3 can be used for Gaucher's disease research[1][2].

• Target Antigen:

  Glucosylceramide Synthase (GCS)

• Type:

  Reference compound

• Related Pathways:

  Neuronal Signaling

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/glucosylceramide-synthase-in-3.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(O[C@H]1CN2CCC1CC2)NC3=CC=CC4=C3N=C(O4)C5=CC=C(C=C5)F

• Molecular Weight:

  381.40

• References & Citations:

  [1]Mali Cosden, et al. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy. Neurobiol Dis. 2021 Nov;159:105507.|[2]Yuta Tanaka, et al. Discovery of Brain-Penetrant Glucosylceramide Synthase Inhibitors with a Novel Pharmacophore. J Med Chem. 2022 Mar 10;65(5):4270-4290

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  3029827-91-3